Frontiers in early detection of hepatocellular carcinoma

Abstract

Description of the article   The need for more precise serodiagnosis marker for hepatocellular carcinoma (HCC) is always a must for many reasons: Serodiagnosis is generally non-invasive and safe technique to have a human sample. Different radiological modalities, although its accuracy is progressing, but many times its result is misinterpreted. The current extensively used seromarker, alpha fetoprotein (AFP), doesn’t exceed 70% for sensitivity and 90% for specificity. Many of clinicians requesting AFP tests, whether in HCC management or related diseases, as, hepatitis C or B infections don’t know exactly the diagnostic accuracy levels of AFP. The need for spectrophotometric marker, rather than molecular or radio or Elisa parameter as a cost effective goal. The earlier the detection of HCC, the longer the patient life.